Switzerland: Leading Case And Amendment Of The Ordinances Regarding The Examination Of Drug Prices

Last Updated: 19 May 2015
Article by Markus Schott and Markus Wang

Most Read Contributor in Switzerland, September 2019

In a leading case of 30 April 2015, the Swiss Federal Administrative Court considered the current practice of the Swiss Federal Office of Public Health (FOPH) regarding the re-examination of drugs which are reimbursed by the mandatory health insurance as unlawful. For the last five years, the FOPH assessed drug prices in the context of periodical re-examinations almost exclusively based on external reference pricing, without considering drug pricing references in Switzerland. In light of this (not yet legally binding) decision, it seems doubtful whether the newest amendments regarding the drug pricing regime enacted by the Federal Council and the Federal Department of Home Affairs will be valid. These amendments are scheduled to come into force on 1 June 2015.

Previous Practice of the Federal Office of Public Health

According to art. 65d para. 1 of the Ordinance on Health Insurance (OHI), the Federal Office of Public Health (FOPH) reviews all drugs included in the list of reimbursable pharmaceutical specialties (Specialties List/SL) every three years in order to determine whether they still comply with the conditions for being listed, that is, whether they are effective, appropriate and efficient. In principle, the fundamental benchmarks to evaluate a drug's efficiency are the Internal Reference Price (IRP) as well as the External Reference Price (ERP), each weighted at 50% (art. 65b para. 2 OHI). However, during the periodic re-examination to be conducted every three years, the ERP is taken into account almost exclusively according to art. 65d para. 1bis lit. a OHI. The IRP is only taken into consideration in exceptional cases, that is, when a comparison with drug prices of reference countries is not feasible. Depending on whether the IRP is included in the examination, the approved drug prices vary.

Limited Examination is not in Accordance with the Law

The Federal Administrative Court's leading case (C-5912/2013) was a about an order of the FOPH that imposed to reduce the price of a specific drug by almost 26% only based on the ERP, without consideration of the IRP.

The Court held that until 2009 it was constant legal practice of the Federal Supreme Court to examine the efficiency of a drug based on both the IRP and the ERP. The cost-benefit-assessment to be conducted in the context of the IRP is to be understood as an essential evaluation criteria regarding a drug's efficiency. Only in cases where no reference drug for the IRP was available and hence the IRP could not be conducted, the ERP could be applied exclusively.

The amendments of the OHI and the Ordinance on Services in the Compulsory Health Insurance (OSCHI) by the Federal Council and the Federal Department of Home Affairs (FDHA) – which were enacted successively since 2009 – aim to reduce the costs of drugs. This was also the goal when art. 65d para. 1bis OHI was adopted with the amendment of the OHI of March 2012. Pursuant to art. 65d para. 1bis OHI, the efficiency shall be assessed exclusively based on the ERP in the context of the triennial review, and the IRP shall only be applicable if the ERP cannot be carried out. As a consequence, the FOPH normally considered the IRP only with respect to the first admission of a drug to the SL.

The Federal Administrative Court held that the adoption of art. 65d para. 1bis lit. a OHI and the elimination of the IRP constituted a fundamental change of the drug pricing regime that clearly contradicts the constant case law of the Federal Supreme Court regarding the concept of efficiency according to art. 32 para. 1 of the Federal Health Insurance Act (HIA). According to the legislator's intent, the same criteria where to apply in the context of the triennial review, as it is the case with respect to the admission of a drug to the SL (efficacy, adequacy, efficiency). The executive branch is not competent to deviate from this statutory concept. Therefore, the court finally held that the rule imposed by art. 65d para. 1bis lit. a OHI violates the constitutional principle of legality. Furthermore, the court stated that the license holder (claimant) may also invoke the constitutional guarantee of economic freedom with regard to the governmental price fixing. Because of its lack of a legal basis, the FOPH order also violates this fundamental right.

The decision of the Federal Administrative Court may be appealed to the Federal Supreme Court and is not yet legally binding.

Amendment of the OHI and the OSCHI to enter into force on 1 Juni 2015

The Federal Council and the FDHA have enacted amendments of the OHI and the OSCHI with regard to drug pricing. These amendments shall enter into force on 1 Juni 2015 and particularly entail the following new rules:

  • When assessing the efficiency with respect to the admission of a drug to the SL, the ERP shall be weighted twice and the IRP only once. As a rule, the newly fixed price may exceed the ERP by no more than 5%.
  • Belgium, Finland, and Sweden will be added to the group of reference countries for the ERP. Moreover, binding discounts in reference countries must be taken into consideration when fixing drug prices in Switzerland.
  • In the context of the triennial review, the ERP must be taken into account for two thirds and the present price for one third. However, the margin of tolerance of 5% currently applicable shall be rescinded. The IRP shall continue to be applied only exceptionally, in particular, if the ERP cannot be carried out at all or only in less than three reference countries.


In its leading case, the Federal Administrative Court interpreted the requirements of the HIA strictly. When conducting the triennial review, the efficiency of a drug is to be assessed based on the same criteria that apply when a drug shall be first admitted to the SL. Both the IRP and the ERP must be applied.

However, the amendment of the OHI and the OSCHI to enter into force on 1 Juni 2015 still stipulate two different types of efficiency tests, one to be followed when assessing the admission of a drug to the SL and the other when conducting the triennial review. Due to its reduced weighting compared to the ERP, the IRP will generally become even less important. As to the triennial review, the IRP will continue to be taken into account only exceptionally.

Given the above, it appears questionable whether said amendment of the OHI and the OSCHI will be valid if the leading case of the Federal Administrative Court becomes legally binding.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions